LUBIPROSTONE - Generic Drug Details

What are the generic drug sources for lubiprostone and what is the scope of freedom to operate?

Lubiprostone is the generic ingredient in two branded drugs marketed by Sucampo Pharma Llc, Amneal, Ascent Pharms Inc, Dr Reddys, Ph Health, Teva Pharms Usa Inc, and Zydus Pharms, and is included in seven NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Lubiprostone has twenty patent family members in fifteen countries.

There are ten drug master file entries for lubiprostone. Nineteen suppliers are listed for this compound.

Summary for LUBIPROSTONE

International Patents:	20
US Patents:	3
Tradenames:	2
Applicants:	7
NDAs:	7
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	19
Raw Ingredient (Bulk) Api Vendors:	77
Clinical Trials:	49
Patent Applications:	2,976
Drug Prices:	Drug price trends for LUBIPROSTONE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUBIPROSTONE
What excipients (inactive ingredients) are in LUBIPROSTONE?	LUBIPROSTONE excipients list
DailyMed Link:	LUBIPROSTONE at DailyMed

See drug prices for LUBIPROSTONE

Recent Clinical Trials for LUBIPROSTONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Third Military Medical University	PHASE3
Ain Shams University	PHASE1
Alexandria University	Phase 3

See all LUBIPROSTONE clinical trials

Pharmacology for LUBIPROSTONE

Drug Class	Chloride Channel Activator
Mechanism of Action	Chloride Channel Activators

Medical Subject Heading (MeSH) Categories for LUBIPROSTONE

Chloride Channel Agonists

Anatomical Therapeutic Chemical (ATC) Classes for LUBIPROSTONE

A06AX	Other drugs for constipation
A06A	DRUGS FOR CONSTIPATION
A06	DRUGS FOR CONSTIPATION
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for LUBIPROSTONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AMITIZA	Capsules	lubiprostone	8 mcg and 24 mcg	021908	1	2012-08-20

US Patents and Regulatory Information for LUBIPROSTONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys	LUBIPROSTONE	lubiprostone	CAPSULE;ORAL	206994-002	Feb 8, 2022	AB	RX	No	No
Teva Pharms Usa Inc	LUBIPROSTONE	lubiprostone	CAPSULE;ORAL	209920-001	Jan 18, 2022	AB	RX	No	No
Zydus Pharms	LUBIPROSTONE	lubiprostone	CAPSULE;ORAL	214131-002	Mar 23, 2023	AB	RX	No	No
Zydus Pharms	LUBIPROSTONE	lubiprostone	CAPSULE;ORAL	214131-001	Mar 23, 2023	AB	RX	No	No

Expired US Patents for LUBIPROSTONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-002	Apr 29, 2008
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-001	Jan 31, 2006
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-001	Jan 31, 2006
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-002	Apr 29, 2008

International Patents for LUBIPROSTONE

Country	Patent Number	Title	Estimated Expiration
Israel	192867
China	101410097	Soft-gelatin capsule formulation
Denmark	1978944
New Zealand	570191	Soft-gelatin capsule formulation comprising a keto-prostaglandin compound

Supplementary Protection Certificates for LUBIPROSTONE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2298314	92826	Luxembourg		PRODUCT NAME: LUBIPROSTONE, INCLUANT LES SELS PHARMACEUTIQUEMENT ACCEPTABLES, LES ESTERS OU LES AMIDES DE LA LUBIPROSTONE. FIRST REGISTRATION: 20120910
1315485	2015C/048	Belgium		PRODUCT NAME: LUBIPROSTONE; AUTHORISATION NUMBER AND DATE: PL21341/0003 20150317
1315485	132016000025193	Italy		PRODUCT NAME: LUBIPROSTONE O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(AMITIZA); AUTHORISATION NUMBER(S) AND DATE(S): PL 21341/0003, 20120910;043833019-021, 20150526
1315485	2015/028	Ireland		PRODUCT NAME: LUBIPROSTONE AND PHARMACEUTICALLY ACCEPTABLE SALTS FOR LUBIPROSTONE.; NAT REGISTRATION NO/DATE: PA148/002/001 20150213; FIRST REGISTRATION NO/DATE: PL21341/0003-0001 20120910

Lubiprostone (Amitiza): Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

How is lubiprostone positioned in the market?

Lubiprostone is a prescription gastrointestinal agent approved for chronic idiopathic constipation (CIC), constipation-predominant irritable bowel syndrome (IBS-C), and opioid-induced constipation (OIC) in adults with certain conditions and population subsets. The drug’s market dynamics are anchored by (1) chronic-use indications with recurring demand, (2) competitive pressure from other constipation and IBS-C therapies, and (3) patent-expiry and life-cycle events that determine pricing power and channel access.

Core commercial framing

• Primary demand drivers: constipation symptom relief in chronic and on-treatment populations.
• Commercial constraints: payer scrutiny for new vs branded products, step edits tied to guideline pathways, and sensitivity to formulary placement.
• Competitive set: other secretagogues and prokinetic/analgesic approaches, plus newer agents in IBS-C and OIC categories that can shift formulary economics.

What do the financials show about the trajectory?

Public financial reporting for specific single-drug sales is typically bundled under company segment reporting or branded drug disclosures. Across the market, lubiprostone’s revenue trajectory follows a pattern common to mature branded GI assets:

• Growth concentrated around initial label expansion and early market penetration.
• Stabilization as competitors gain footprint and payer restrictions increase.
• Gradual decline in peak markets once competitive erosion is established and exposure shifts toward broader formularies and step-therapy.
• Renewed volatility tied to generics, biosimilars (not directly relevant here), or manufacturer-specific contracting and channel changes.

Sales directionality (industry typical pattern)

• Post-label-expansion phase: higher growth and market expansion.
• Maturity phase: revenue plateaus, with growth dependent on incremental formulary wins and adherence.
• Late-cycle phase: pressure from therapeutic alternatives and price/mix effects.

Because the drug’s financial profile is sensitive to payer contracts and dispensing channel shifts, the most decision-relevant metric is branded unit share and net price rather than list price. That is where competitive dynamics show up first: formulary status, prior authorization rates, and patient switching.

What market dynamics shape revenue and unit demand?

1) Indication breadth drives recurring demand

Lubiprostone is used across multiple constipation-related indications. Each indication differs in:

• Eligibility rules (adult populations, diagnostic criteria).
• Persistence and discontinuation patterns.
• Payer access policies (step therapy and trial requirements).

Broad label coverage tends to reduce demand volatility, but it does not immunize revenue from competitive entrants that target the same symptoms with different mechanisms.

2) Formulary access and step therapy dominate

For GI symptom treatments, revenue is influenced less by clinical claims than by:

• Managed-care formulary tier placement
• Prior authorization criteria
• Preferred alternatives by payer category
• Quantity limits and duration controls in certain OIC sub-populations

When payers tighten access for branded products, net revenue typically compresses even if prescriptions continue.

3) Competitive mechanism substitution is real

Constipation and IBS-C remain one of the most contested branded GI therapeutic areas. Patients and prescribers can move between classes based on:

• Efficacy perceptions and side-effect tolerability
• Dosing convenience
• Coverage stability for long-term therapy

Lubiprostone faces continuous substitution risk from branded and non-branded therapies with overlapping symptom targets.

4) Specialty pharmacy and distribution contracts affect net results

For chronic GI drugs, net sales are shaped by:

• Contracted discounts and rebates
• Channel inventory adjustments
• Mix between commercial vs government programs
• Distribution partner terms in different geographies

Those factors typically drive “flat to down” brand-year results even when prescription counts remain stable.

How do patent and life-cycle events affect pricing power?

Patent expiry and exclusivity are the primary inflection points for branded revenue trajectories. For lubiprostone, the market has historically been influenced by:

• Entry timing and speed of generic competition in major markets
• Continued branded supply strategy and contracting
• Switching behavior from prescribers and payers once generic alternatives are available

Commercial consequence: once generic competition is established, branded net price usually compresses rapidly through rebate pressure, formulary downgrades, and patient switching.

Where does competitive pressure show up first: utilization or net price?

In mature GI brands, competitive pressure typically surfaces in two steps:

Step A: Utilization shift

• Payers steer to preferred products (therapeutic substitution).
• Prescribers adjust prescribing habits after access changes.
• Patients switch due to out-of-pocket differentials.

Step B: Net price compression

• Even if utilization holds, net price decreases via rebate renegotiations.
• Product mix shifts (commercial share declines faster than government programs).
• Inventory dynamics can temporarily distort revenue but not cure structural price erosion.

For lubiprostone, the practical business takeaway is that unit demand can lag net revenue decline by quarters, while net sales respond sooner when payer contracts tighten.

What does payer economics imply for future demand?

Managed care economics in constipation and IBS-C drive long-term outcomes through:

• Tiering outcomes and co-pay design
• Prior authorization and step therapy protocols
• Plan-level budget targeting

This typically reduces the addressable market for branded product over time, while preserving baseline demand among:

• Patients already established and stable on therapy
• Physicians with strong adherence patterns
• Plans that continue to cover lubiprostone without onerous restriction

The result is a “floor” demand pattern that can persist even after competitive entry, but with lower revenue per prescription.

How should investors and strategics read the revenue curve?

For a drug like lubiprostone, the revenue curve generally reflects three overlapping curves:

1. Prescriptions (demand): influenced by patient pool and switching.
2. Net price: influenced by formulary access, rebates, and payer mix.
3. Channel/contract effects: influenced by supply and inventory timing.

Business decision-making should focus on:

• Branded prescription share and share-of-voice within constipation classes
• Net sales per prescription (a proxy for pricing pressure)
• Payer penetration rates in top plans (leading indicator)

What are the key market risks and commercial levers?

Key risks

• Therapeutic substitution: new and existing alternatives for IBS-C and OIC shift patient flows.
• Formulary narrowing: branded relegation to lower tiers and increased prior authorization.
• Net price compression: rebate pressure and contract renegotiations.
• Generic switching: loss of branded share once generic availability expands.

Commercial levers

• Clinical positioning and tolerability messaging: supports persistence in treated patients.
• Contracting strategy: targets rebate and formulary outcomes in top accounts.
• Indication-specific stewardship: aligns prescribing to sub-populations with better persistence.
• Access programs (where applicable): reduces patient cost friction and supports adherence.

What is the practical financial trajectory expectation?

Given typical branded GI market behavior and competitive pressure, lubiprostone’s financial trajectory is expected to:

• Move from expansion toward maturity
• Then transition toward steady declines post-erosion
• With possible temporary stabilization during contracting resets or shifts in payer coverage patterns

The direction of travel is driven by structural payer dynamics and generic substitution, not by incremental clinical outcomes at this stage of product life.

Key Takeaways

• Lubiprostone’s demand is structurally supported by chronic constipation indications, but revenue is highly sensitive to payer access and net price compression.
• Financial trajectory in mature branded GI markets typically follows a sequence: plateau, then downshift driven first by utilization mix and then by net price.
• Patent and generic-entry dynamics are decisive for pricing power and branded share loss.
• For business decisions, the leading indicators are formulary tiering outcomes, net sales per prescription, and branded share within constipation and IBS-C therapeutic classes.

FAQs

1) What drives lubiprostone revenue most in the late-cycle phase?
Net price driven by formulary tier placement, rebates, and contract renegotiation, followed by branded share loss to alternatives and generics.

2) Does the drug face mainly utilization risk or pricing risk first?
Utilization mix shifts first through formulary steering and prescribing changes; net price compression follows through rebate pressure and access changes.

3) Why do constipation indications tend to have steadier demand than acute therapies?
Because symptoms and treatment adherence occur over longer periods, producing recurring prescription patterns conditional on access and tolerability.

4) How should investors benchmark financial trajectory for lubiprostone?
Track net sales per prescription, branded share in constipation/IBS-C, and top-plan formulary coverage changes rather than list price alone.

5) What is the most common inflection event for branded GI drugs?
Generic entry and subsequent payer switching behavior that systematically reduces branded volume and compresses net price.

---

References

[1] U.S. Food and Drug Administration. Amitiza (lubiprostone) prescribing information. FDA label.
[2] American College of Gastroenterology. Guidelines for IBS-C and constipation management.
[3] SSRN/industry analyses and market access literature on managed care formulary dynamics for chronic GI therapies (general payer behavior).